1 Step Closer To Personalized Medicine: Stroma Genomic Signature Predicts Resistance To Anthracyclin-Based Chemotherapy In Breast Cancer

News — By on February 4, 2009 at 7:00 am

Researchers at the Swiss Institute of Bioinformatics and the Swiss National Center of Competence in Research in Molecular Oncology in Lausanne have developed a new test to predict how breast cancer patients respond to chemotherapy, which could help change how treatment is delivered in the future.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback